Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. Grants Special Equity Award to CEO Yvonne Greenstreet
Summary
Alnylam Pharmaceuticals, Inc. granted a special equity award to its Chief Executive Officer, Yvonne Greenstreet, M.D., M.B.A., under the Company's Second Amended and Restated 2018 Stock Incentive Plan. The award is fully performance-based and contingent upon the achievement of significant stock price appreciation by December 31, 2029. The Board of Directors views this award as a strategic tool to incentivize and retain Dr. Greenstreet, ensuring sustained leadership and stability as the company embarks on its next phase of growth.
Profitelligence Alerts
Get alerts for ALNY
Be first to know when Alnylam Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.
Official SEC Documents
Advertisement